Skip to main content

Fears over Fast-Tracking Drugs

Doctors question whether a government initiative to speed approval for promising new drugs is ensuring safety.

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00

Drugs given Fast Track review by the US Food and Drug Administration (FDA) may have higher health risks and more side effects, argue two authors last week (September 5) in the Journal of the American Medical Association (JAMA).

In 2011, the FDA expedited approval for nearly half of all 35 new drugs it reviewed. Many of the drugs chosen for the Fast Track process are aimed at treating ailments with unmet medical needs, such as certain types of cancer and multiple sclerosis. In their article, the JAMA authors focus on three drugs—vandetanib, fingolimod, and dabigatran—that were approved despite serious toxicity and concerns regarding safe dosing. As an example, the blood thinner dabigatran (also called Pradaxa) was approved for lowering the risk of stroke in patients with irregular heart beat. However, within less than a year, “Pradaxa accounted for more serious adverse drug events reported to the FDA during the second ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Placeholder image

    Edyta Zielinska was a senior editor at The Scientist from 2007 to 2013, where she worked closely with scientific illustrators to develop accompanying graphics to illuminate complex concepts. 

    View Full Profile

Related Topics

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
Engineering Bispecific Antibodies Against Emerging Viruses

Engineering Bispecific Antibodies Against Emerging Viruses

innovative-research-horizontal-lock-inverted-rgb-900px-w-72ppi
Advancing Research With Humanized Mouse Models

Advancing Research with Next-Generation Humanized Mouse Models

bioxcell
3d illustration showing amyloid plaques in Alzheimer's disease

Best Practices for Blood-Based Amyloid Pathology Testing

fujirebio logo
Optimizing Critical Steps in T-Cell Engineering

Optimizing Critical Steps in T-Cell Engineering

Fujifilm

Products

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation

A photograph of plastic fragments floating in water, symbolizing contamination from sample storage tubes.

LVL SAFE® 2D-Coded Tubes: The Perfect Tube for Your Sample

AutoGen